(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/209940 A1

(51) International Patent Classification:
A61P 31/20 (2006.01) *A61K 39/42* (2006.01)
A61K 39/12 (2006.01) *A61K 39/00* (2006.01)
C07K 16/08 (2006.01)

(21) International Application Number:
PCT/EP2025/058562

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24167961.2 31 March 2024 (31.03.2024) EP
63/572,614 01 April 2024 (01.04.2024) US

(71) Applicant: **HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)** [DE/DE]; Ingolstaedter Landstrasse 1, 85764 Neuherberg (DE).

(72) Inventors: **HAMMERSCHMIDT, Wolfgang**; c/o Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstaedter Landstrasse 1, 85764 Neuherberg (DE). **PICH, Dagmar**; c/o Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstaedter Landstrasse 1, 85764 Neuherberg (DE). **MAUTNER, Josef**; c/o Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstaedter Landstrasse 1, 85764 Neuherberg (DE).

(74) Agent: **WEINZIERL, Gerhard** et al.; Schiweck Weinzierl Koch Patentanwälte, Partnerschaft mbB, Ganghoferstrasse 68B, 80339 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: EBV VACCINE AND ANTIBODIES

(57) Abstract: The present invention relates, inter alia, to a composition comprising the BILF2 glycoprotein of Epstein-Barr-Virus (EBV), a nucleic acid encoding the BILF2 glycoprotein of EBV, or an extracellular vesicle (EV) or EB-virus-like particle (VLP) displaying at its surface the BILF2 glycoprotein of EBV, for use in a method of eliciting antibodies against said BILF2 glycoprotein which reduce infectivity of EBV for human epithelial cells. Preferably, said composition elicits antibodies that prevent infection of human epithelial cells by EBV.

WO 2025/209940 A1